1 **TITLE PAGE**

2

28

3 A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous 4 5 meningitis (The LASER-TBM Trial) 6 Angharad G Davis (corresponding author)^{1,2,3}, Sean Wasserman^{3,4}, Cari Stek^{3,5}, Mpumi 7 Maxebengula³, C. Jason Liang⁶, Stephani Stegmann³, Sonya Koekemoer³, Amanda 8 Jackson³, Yakub Kadernani³, Marise Bremer³, Remy Daroowala^{3,5}, Saalikha Aziz³, Rene 9 Goliath³, Louise Lai Sai³, Thandi Sihoyiya³, Paolo Denti¹⁴, Rachel PJ Lai^{1,5}, Thomas Crede⁷, 10 Jonathan Naude⁷, Patryk Szymanski⁷, Yakoob Vallie⁸, Ismail Abbas Banderker⁸, Muhammed 11 12 S Moosa⁸, Peter Raubenheimer⁴, Sally Candy⁹, Curtis Offiah¹⁰, Gerda Wahl¹¹, Isak Vorster⁹, Gary Maartens^{3,12}, John Black¹¹, Graeme Meintjes^{3,4}, Robert J Wilkinson (co-corresponding 13 author)1,2,3,4,5 14 15 16 **Corresponding author:** Angharad Davis, The Francis Crick Institute, 1 Midland Road, 17 London NW1 1AT; Email: angharad.davis@crick.ac.uk; Phone: +44 2037966956 **Co-corresponding author**: Robert J Wilkinson, The Francis Crick Institute, 1 Midland Road, 18 19 London NW1 1AT; Email: robert.wilkinson@crick.ac.uk; Phone: +44 2037966956 20 **SUMMARY**: In this phase 2a randomised control trial we demonstrate that high-dose 21 22 rifampicin and adjunctive linezolid is safe in adult HIV-associated tuberculous meningitis. Larger studies are required to evaluate potential toxicity with aspirin, in relation to benefit on 23 morbidity and mortality. 24 25 26 Keywords: Tuberculous meningitis; HIV; rifampicin; linezolid; aspirin 27 Word count: 3500 words NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. Table count: 5; Figure count: 6

29 AFFILIATIONS

- 30 1. The Francis Crick Institute, Midland Road, London, NW1 1AT, United Kingdom
- 31 2. Faculty of Life Sciences, University College London, WC1E 6BT, United Kingdom
- 32 3. Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious
- 33 Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Republic of
- 34 South Africa
- 4. Department of Medicine, University of Cape Town, Observatory 7925, Republic of South
- 36 Africa
- 37 5. Department of Infectious Diseases, Imperial College London, W12 0NN, United Kingdom
- 38 6. Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases,
- 39 Maryland, USA
- 40 7. Mitchells Plain Hospital, 8 A Z Berman Drive, Lentegeur, Cape Town, 7785, South Africa
- 41 8. New Somerset Hospital, Portswood Rd, Green Point, Cape Town, 8051, South Africa
- 42 9. Division of Diagnostic Radiology, University of Cape Town, Groote Schuur Hospital,
- 43 Observatory 7925, Republic of South Africa.
- 44 10. Department of Neuroradiology, Imaging Department, Royal London Hospital, Barts
- 45 Health NHS Trust, Whitechapel, London, E1 1BB, United Kingdom
- 46 11. Department of Medicine, Walter Sisulu University, Mthatha 5117, Republic of South
 47 Africa
- 48 12. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town,
- 49 Observatory 7925, Republic of South Africa
- 50

51 FUNDING

- 52 AGD is supported by a UCL Wellcome Trust PhD Programme for Clinicians Fellowship
- 53 (award number 175479). SW is supported by the European & Developing Countries Clinical
- 54 Trials Partnership (Grant number CDF1018), Wellcome (Grant number 203135/Z/16/Z and
- 55 104803), and National Institutes of Health (K43TW011421). RL is supported MRC CDA
- 56 Fellowship (MRC/R008922/1). RJW receives support from Wellcome (104803; 203135) as

57	well as the Francis Crick Institute which is funded by UKRI (FC0010218); Wellcome
58	(FC0010218) and CRUK (FC0010218). He also receives support from Meningitis Now and
59	NIH (R01AI45436). GrM is supported by Wellcome Trust (214321/Z/18/Z), and the South
60	African Research Chairs Initiative of the Department of Science and Technology and
61	National Research Foundation (NRF) of South Africa (Grant No 64787). For the purposes of
62	open access the authors have applied a CC-BY public copyright licence to any author
63	accepted manuscript arising from this submission.
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	

85 ABSTRACT

86

Background: Drug regimens which include intensified antibiotics alongside effective antiinflammatory therapies may improve outcomes in Tuberculous Meningitis (TBM). Safety
data on their use in combination and in the context of HIV is needed to inform clinical trial
design.

91

Methods: We conducted a phase 2 open-label parallel-design RCT to assess safety of highdose rifampicin, linezolid and aspirin in HIV-associated TBM. Participants were randomised (1.4:1:1) to three treatment arms (arm 1, standard of care (SOC); arm 2 SOC + additional rifampicin (up to 35mg/kg/day)) + linezolid 1200mg/day reducing after 28/7 to 600mg/day; arm 3, as per arm 2 + aspirin 1000mg/day) for 56 days, when the primary outcome of adverse events of special interest (AESI) *or* death was assessed.

98

99 **Results:** 52 participants were randomised. 59% had mild disease (MRC Grade 1) vs 39% 100 (Grade 2) vs 2% (Grade 3). 33% of participants had microbiologically-confirmed TBM; vs 101 41% 'possible' or 25% 'probable'. AESI or death occurred in 10/16 (arm 3) vs 4/14 (arm 2) 102 vs 6/20 (arm 1) (p=0.083). The cumulative proportion of AESI or death (Kaplan-Meier 103 method) demonstrated worse outcomes in arm 3 vs arm 1 (p=0.04), however only one event 104 in arm 3 was attributable to aspirin and was mild. There was no difference in efficacy 105 (Modified Rankin Scale) at day 56 between the three arms.

106

Conclusions: High-dose rifampicin and adjunctive linezolid can safely be added to SOC in
 HIV-associated TBM. Larger studies are required to evaluate whether potential toxicity
 associated with these interventions, particularly aspirin, is outweighed by mortality or
 morbidity benefit.

111

112

113 INTRODUCTION

114

Tuberculous meningitis (TBM) is the most severe form of tuberculosis. With currently 115 116 available treatment mortality is high; up to 50% in those co-infected with HIV¹. In those who 117 survive, there is a high burden of disability due to neurological sequelae such as stroke², epilepsy³, inflammatory complications within the spinal cord⁴ and neurocognitive 118 impairment⁵. Drug regimens used to treat TBM are largely based on those used in 119 120 pulmonary tuberculosis. There is a need to design and evaluate new regimens that account 121 for the differing ability of drugs to penetrate the central nervous system (CNS) whilst 122 simultaneously counteracting the dysregulated immune response which occurs in TBM in 123 order to improve outcomes in this disease. 124 Rifampicin at standard adult doses seldom achieves adequate cerebrospinal fluid (CSF) 125 concentrations ⁶; it is therefore likely that higher doses would increase bactericidal activity 126 127 within the CNS. Two randomised controlled trials (RCT) in TBM have evaluated high-dose 128 rifampicin (13mg/kg intravenous⁷ and 15mg/kg oral⁸) with conflicting results. A recent 129 pharmacokinetic (PK) study suggested that doses higher than 15mg/kg may improve 130 outcomes by demonstrating ~8 and ~6 fold higher CSF exposures with 35mg/kg (oral) and 20mg/kg (IV) doses respectively compared to standard oral dose (10mg/kg)⁹. Linezolid, 131 132 which is now part of the WHO recommended treatment in drug resistant TB¹⁰, is known to have broad tissue penetration, including into the CNS¹¹. Two observational studies of 133 134 linezolid found favourable clinical and laboratory outcomes in both children and adults with 135 TBM^{12,13}. However, frequently reported haematological and neuropathic toxicity are concerning¹⁴. In TBM this toxicity, which is rarely severe¹⁵ and largely reversible¹⁶, may be 136 acceptable. Aspirin targets key pathogenic processes which occur during TBM: inhibition of 137 thromboxane and platelet aggregation¹⁷ at lower doses (75mg daily), and inhibition of 138 proinflammatory prostaglandins and thromboxane A₂¹⁸ at higher doses (>600mg daily). The 139 140 latter may be further augmented by aspirin's ability to trigger production of pro-resolving lipid

141 mediators¹⁹. Three RCT have evaluated aspirin at varying doses (from 75mg daily to 1000mg/day) with varying outcomes in TBM²⁰⁻²². The latest of these demonstrated reduction 142 143 in infarcts and death with 1000mg of aspirin compared to placebo in HIV-negative patients with microbiologically confirmed TBM²⁰. The safety of high-dose aspirin, which may lead to 144 145 anti-inflammatory effects, has yet to be evaluated in the context of HIV and in conjunction 146 with adjunctive antimicrobial drugs. 147 A number of clinical trials are investigating either the PK properties of linezolid 148 149 (NCT04021121, NCT03537495) or efficacy of high-dose rifampicin (ISRCTN15668391) as 150 single adjunctive therapies in TBM, and one phase 3 trial aims to assess efficacy of linezolid, 151 high-dose rifampicin, and lower-dose aspirin (NCT04145258). However, safety data on the 152 use of rifampicin and linezolid in combination, of high-dose aspirin in combination with 153 intensified antibiotics, and in the context of HIV co-infection is absent. LASER-TBM aimed to 154 generate much needed safety data on the use of enhanced antimicrobial therapy including 155 higher-dose rifampicin (35mg/kg) and linezolid (1200mg reducing to 600mg daily) with or 156 without adjunctive high-dose aspirin (1000mg daily) in HIV-associated TBM, to inform their 157 use in definitive clinical trials.

158

159 METHODS

160

LASER-TBM was an open label, parallel group, randomised, multi-arm phase 2A trial in
which participants were randomised to one of three treatment arms as specified below.
Investigational drugs were given for the first 56 days of therapy. Primary endpoint data was
collected at day 56. Treatment was subsequently continued per South African national
guidance. Participants completed study follow up at 6 months. Interim analysis for safety
was performed by an independent data safety monitoring board (DSMB) board after every
participants enrolled. A full version of the study protocol is published elsewhere²³.

168

169 Study participants and sites

- 170
- 171 Adults aged 18 or over with a diagnosis of possible, probable or definite TBM as per uniform
- 172 case definition²⁴, and a confirmed HIV-1 seropositivity were eligible for enrolment. Exclusion
- 173 criteria are listed in Box S1 (supplementary appendix). Written informed consent was
- 174 obtained from participants where individuals were assessed to have capacity; in those
- 175 without capacity to consent, proxy consent from next of kin was obtained. In the latter cases
- deferred consent was obtained from the patient as soon as they were able.
- 177 Potential participants were referred whilst inpatients at four regional referral hospitals across
- 178 South Africa. Subsequent follow-up occurred in inpatient wards and outpatient clinics at
- 179 respective sites, or at two TB hospitals in Cape Town.
- 180

181 Intervention

- 182
- 183 Participants were randomised to one of three treatment arms (1.4:1:1). Proportionally more
- 184 participants were randomised to arm 1 to account for anticipated higher mortality with
- 185 standard of care, compared to the intervention arms.
- 186
- Arm 1 (standard of care): rifampicin 10 mg/kg, isoniazid (H) 5 mg/kg, ethambutol (E)
 15 mg/kg, and pyrazinamide (Z) 25 mg/kg daily for 56 days
- Arm 2: as per arm 1 plus adjunctive 25mg/kg rifampicin (total dose 35mg/kg) and
 linezolid (1200mg for 28 days, reducing to 600mg for 28 days) daily for 56 days
- Arm 3: as per arm 2 plus adjunctive aspirin (1000mg) daily for 56 days
- 192
- 193 Dosing was calculated by weight bands as published in the study protocol²³. After 56 days
- 194 participants were referred to government TB facilities to receive continuation therapy
- 195 (rifampicin 10mg/kg/day and isoniazid 5mg/kg/day) for 7 months as per national South
- 196 African guidelines²⁵.

19	97
_	

198 Participants allocated to arms 2 and 3 were further randomised (1:1) to receive oral 199 rifampicin 35 mg/kg or IV rifampicin 20 mg/kg once daily for the first 3 days of therapy (in 200 addition to HZE and linezolid with or without aspirin, according to the experimental arm). 201 Results of this PK sub-study are published elsewhere²⁶. 202 203 **Outcome Measures** 204 205 The primary endpoint of the study was the cumulative proportion of participants experiencing 206 AESI or dying by 56 days. AESI were selected based on anticipated toxicity related to the 207 two interventional arms: bleeding (gastrointestinal bleeding and intracerebral haemorrhage); 208 haematological (anaemia, neutropenia, thrombocytopenia); transaminitis; and neuropathic 209 (peripheral and optic neuropathy) (see Table 1). Secondary endpoints included death and 210 severe disability by 56 days, death by 56 days and 180 days; disability at 56 and 180 days; 211 incidence of grade 3 or 4 adverse events, permanent discontinuation of study drugs, severity 212 and frequency of haematological and neurological AESI related to linezolid use; severity and 213 frequency of major bleeding (gastrointestinal and intracerebral) related to aspirin use; 214 occurrence of TBM-Immune Reconstitution Inflammatory Syndrome (IRIS) assessed by the 215 modified International Network for the Study of HIV-associated IRIS (INSHI) criteria²⁷; and 216 MRI and CT changes at day 56. 217 Study schedule and safety outcome measures 218 219 220 Participants were screened and enrolled within 5 days of commencing TB treatment. They 221 were assessed at five subsequent study visits (days 3, 7, 14, 28, 56) at which point they 222 were referred to government TB clinics for continuation phase therapy (Figure S1). 223 Participants were assessed clinically at one further timepoint (day 180) either in person or 224 telephonically. Where feasible, imaging (either CT and/or MRI) was performed at baseline

225 and day 56. A neurological assessment including full motor and sensory examination of the 226 limbs and cranial nerve examination was performed at each study visit. Participants' 227 functional neurological status was assessed using the Modified Rankin Scale at each study 228 visit up to day 56 and telephonically at day 180. Assessment for AESI was also made at 229 each study visit up to and including day 56 involving; a clinical history to assess symptoms of bleeding (GI or intracerebral), BPNS and modified total neuropathy score to assess for 230 231 peripheral neuropathy, a LogMAR or tumbling E charts to assess for optic neuropathy, a full 232 blood count to assess for haematological abnormalities and liver function tests to assess for 233 a transaminitis. A full list of clinical outcome measures and assessments performed at each 234 study visit are listed in the published protocol²³. 235 236 Study oversight 237 238 An independent DSMB oversaw the safety of the trial and advised to continue recruitment 239 without change after review of primary endpoint data for each 15 participants enrolled. No 240 formal stopping rules were stipulated but rather were left to the discretion of the DSMB. 241 242 Approval for the trial was granted by the University of Cape Town Human Research Ethics 243 Committee (293/2018), Walter Sisulu University Human Research Committee (012/2019) and the South African Health Products Regulatory Authority (20180622). The trial was 244 registered on the South African National Clinical Trials Register (DOH-27-0319-6230), Pan 245 African National Clinical Trials Register (PACTR201902921101705) and clinicaltrials.gov 246

- 247 (NCT03927313).
- 248
- 249
- 250
- 251
- 252

253 STATISTICAL ANALYSIS

254

255 Sample size

No formal statistical power calculation was performed. Even as single adjunctive therapies 256 257 there was limited available data on the use of these drugs in TBM to predict likely rate of 258 AESI and/or death. Given this would be further complicated when considering likely event 259 rate when the drugs were combined, it was felt a more pragmatic approach was to create a 260 recruitment target of 100 participants with frequent blinded review of cumulative safety 261 events by an independent DSMB. An aim of LASER-TBM was also to serve as a planning 262 study to generate PK and safety data to inform a phase 3 RCT of intensified treatment in 263 TBM (NCT04145258), which in part would influence resulting sample size of that study. The 264 rate of recruitment was slower than anticipated due to the COVID-19 pandemic and in 265 January 2021 a decision was made, in consultation with the DSMB, to cease recruitment to 266 allow commencement of the aforementioned phase 3 RCT.

267

268 Statistical analysis

269

Analysis was performed in GraphPad Prism v.9.0 and R v.3.6.0. The primary analysis was performed in the modified intent-to-treat population (those who receive any dose of the study drug). A sensitivity analysis was planned for the per-protocol population (those who completed treatment as specified in the protocol) however given the small sample size and since these populations were similar, here we report the most conservative analysis (modified intention to treat).

276

The primary endpoint, frequency of AESI or death (where data is censored at the first event prior to day 56) was summarized and compared across arms using a chi-squared test. A time to event analysis was performed for worst grade (in each individual participant) AESI or death; comparisons between study groups were made using the log-rank test. Neurological

281 disability (measured by Modified Rankin Score), as well as radiological outcomes at day 56 282 were compared across treatment arms using chi-squared test. We used spaghetti plots to visually represent longitudinal CSF parameters (lymphocytes, polymorphonuclear cells, 283 284 protein and glucose) over time and used t tests to compare longitudinal summaries (mean 285 and SD) of each individual trajectory across treatment arms. 286 287 Details of further analysis can be found in the full statistical analysis plan published alongside the study protocol²³. 288 289 290 RESULTS 291 292 98 patients were screened and 52 were randomised between June 2019 and January 2021 293 (Figure 1). Reasons for screening exclusion are summarised in Table S1. One participant 294 was randomised but excluded prior to any study IP being dispensed due to emergence of an 295 exclusion criterion (eGFR <20) on a hospital blood test performed prior to randomisation. 296 Another participant was excluded from the modified intention to treat analysis as they died 297 prior to receiving any dose of study drug. Six participants discontinued the study prior to day 298 56, and a further four participants discontinued between day 56 and day 180 (Table S2). 299 300 The baseline characteristics of the participants stratified by treatment arm are described in 301 Table 1. Most participants were male (71%) and the median age was 39 (34-46). Most 302 participants had mild disease (MRC Grade 1 59%; Grade 2 39%; Grade 3 2%). A third (33%) of participants had microbiologically confirmed TBM at baseline, with the remaining 303 304 participants defined as possible (41%) or probable TBM (25%) as per the uniform TBM case definition²⁴. 305 306 307 The primary endpoint analysis was performed in the modified intention to treat population

308 (n=50; arm 1, 20; arm 2, 14; arm 3, 16). The composite primary endpoint of AESI or death

309 occurred in 6/20 in arm 1, 4/14 in arm 2, and 10/16 participants in arm 3, (p=0.083). The 310 occurrence of each category of AESI stratified by treatment arm are summarised in table 3 311 with further detail on timing and outcome of each of these events listed in table 4. Frequency 312 of death prior to day 56 was similar across arms (n=7; arm 1, 3; arm 2, 1; arm 3, 3; p=0.649) 313 and in no case was cause of death related to study investigational product (table 5). Grade 3 314 or 4 AE (grade 3: arm 1, 7 vs arm 2, 7 vs ar, 3, 9, p=0.44; grade 4: arm 1, 2 vs arm 2, 4 vs 315 arm 3, 4, p=0.38) or serious adverse events for reasons other than death (arm 1, 6 vs arm 2, 316 8 vs arm 3, 7, p=0.37) were similar across treatment arms.

317

The cumulative incidence of the composite endpoint of worst grade AESI or death at day 56 demonstrated worse outcomes when comparing arm 3 vs arm 1 (p=0.043), with similar proportions observed in other pre-specified analysis (arm 2 vs arm 1 (p=0.3), arm 2+3 combined vs arm 1 (p=0.5)) (Figure 2, log rank test). Similarly, analysis for death alone demonstrated no difference between arms (Figure 3). The cumulative incidence of AESI events was greater in arm 3 vs arm 1 (p=0.02), however, when arms 2 and 3 were combined and compared to arm 1 this difference was less marked (p=0.18) (Figure 4).

325

326 The frequency of grade 5 MRS (severe disability) or death was 4 (arm 1) vs 3 (arm 2) vs 5 327 (arm 3), p=0.774. The frequency of good (defined as MRS grade 0-3), and bad outcomes (MRS Grade 4-6) were similar across arms (p=0.616) (Figure 5). Post hoc analysis of 328 change in neurological function (as measured by MRS) found similar changes of MRS from 329 330 baseline to day 56 between the three arms (Figure 4a). Few IRIS events occurred (arm 1, 2; arm 2, 2; arm 3, 3), of which 4/7 were defined as neurological IRIS. Within the first 56 days 331 332 of treatment, four participants developed new onset lower limb weakness (TB myelopathy 2; 333 TB radiculomyelopathy/arachnoiditis 1; other (no cause found prior to death) 1); three 334 participants developed a new onset hemiplegia; one patient developed a new onset isolated 335 cranial nerve palsy (lower motor neuron VII). Thirteen participants presented with new onset 336 seizures at TBM diagnosis. A further nine participants had new onset seizures within the first

337	2 months of follow up (arm 1, 5; arm 2; 2; arm 3, 2; <i>p</i> =0.54). Baseline and follow up imaging
338	was performed in only 9 patients at the timepoints pre-specified within the protocol. Follow
339	up imaging demonstrated new or worsening leptomeningeal enhancement in 2/9 participants
340	(arm 1 and arm 2), new evidence of infarction in 2/9 participants (arm 1 and arm 2), new or
341	worsening tuberculomas in 2/9 participants (arm 1 and arm 2) which was associated with
342	worsening sulcal effacement in 1/9 participant (arm 1).
343	
344	Spaghetti plot analysis of longitudinal CSF parameters (lymphocyte and polymorphonuclear
345	cell count, protein and glucose) over time demonstrated downward trend of parameters
346	across all three treatment arms (figure 6). Individual values are plotted and the
347	superimposed line represents the mean values at each timepoint in each treatment arm. T
348	tests comparing mean and variance at each time point demonstrated no difference between
349	arms.
350	
351	
352	DISCUSSION
353	
354	The LASER-TBM study was a phase 2a RCT which evaluated the safety of high-dose
355	rifampicin (35mg/kg daily), adjunctive linezolid (1200mg reducing to 600mg after 28 days)
356	and adjunctive aspirin (1000mg daily) for the first 56 days of treatment in HIV-associated
357	TBM. Primary endpoint analysis showed no significant difference in the incidence of AESI or
358	death between treatment arms, although there was a trend towards an increase in events in
359	arm 3. There was no difference in death or disability at day 56 across arms; and a similar
360	frequency of clinical or radiological events occurred in each arm. Exploratory analysis found

Although secondary analysis revealed a significantly higher number of events (AESI or death) in arm 3 vs arm 1 (p=0.04), it is reassuring that no deaths were attributed to aspirin.

no difference in change in CSF parameters over time by arm.

365 Only one bleeding event occurred, after minimal exposure to high-dose aspirin (1 dose), resolved immediately following discontinuation of the drug, and was not associated with any 366 367 laboratory markers to suggest significant gastrointestinal bleeding. Toxicity attributable to 368 linezolid was similarly mild; of seven events potentially attributable to linezolid occuring in 369 participants randomised to experimental arms, 3/7 were due to an alternative cause and 2/7 370 had recovered prior to the subsequent study visit. No patient was formally diagnosed with 371 peripheral neuropathy, which is expected given most recent studies showing a median time to onset of neuropathy occurs after 10 weeks of treatment^{15,16}. Only one participant 372 373 developed a change in visual acuity, which may have been due to linezolid, although on 374 review by an ophthalmologist was assessed more likely due to ethambutol. The number of 375 participants in whom potential abnormalities were detected using the LogMAR and tumbling 376 E assessments, compared to the confirmed number of cases of optic neuropathy calls into 377 question the specificity of these outcome measures. Given that linezolid has potential to 378 treat TBM as well as drug resistant TB we must consider whether better outcome measures 379 can be developed to reliably detect abnormalities attributable to these drugs in both the 380 clinical and research setting in order to prevent overestimation of toxicity, particularly when 381 used for a short duration. Toxicity due to rifampicin was similarly infrequent with only two 382 participants developing clinically significant transaminitis. In both cases the transaminitis 383 recovered with treatment interruption. These results suggest that toxicity associated with the enhanced antitubercular regimen (rifampicin 35mg/kg and adjunctive linezolid) is not 384 common when used in combination for two months to treat HIV-associated TBM. This is 385 encouraging in the context of a disease where no specific evidenced-based antitubercular 386 regimen exists, and provides rationale for the ongoing phase 3 RCT (NCT04145258) where 387 388 participants are randomised to receive both high-dose rifampicin and linezolid at doses 389 identical to that used in this study.

390

There are several limitations to this study. Although no formal power calculation took place,final sample size was substantially smaller than the target of 100 participants. The COVID-

393 19 pandemic adversely affected recruitment to the study, and in January 2021 a decision 394 was made to stop recruitment to enable commencement of a similar phase 3 study which 395 was ready to start resulting in a lower than proposed sample size. It is unknown whether the 396 significantly higher number of AESI or death in arm 3 vs arm 1 demonstrated within the 397 secondary analysis reflects a true safety risk of the regimen containing aspirin, or is due to 398 chance given the lower than anticipated numbers of participants recruited. Secondly, the 399 majority participants recruited had mild TBM. The reasons for this is likely multifactorial 400 including i) patients dying prior to screening given that up to 5 days of TB treatment was 401 allowed prior to enrolment and ii) patients with decreased levels of consciousness arriving at 402 hospital alone and therefore not having available next of kin available for proxy consent. In 403 the latter case a protocol amendment was approved to allow deferred consent in these 404 patients, however, is likely to explain in part the higher rate of mild disease in our cohort. 405 The mild level of disease within our patient cohort likely explains the low level of mortality; 406 16% 2-month mortality contrasted the oft quoted 50% mortality within the literature¹. The 407 primary endpoint of AESI or death was designed with the assumption that observed mortality 408 would be near or approaching 50%. The relatively few numbers of deaths led to a greater 409 proportion of AESI in the composite endpoint of AESI or death. Given that all of the listed 410 AESI were proportionally more likely to occur in the experimental arm 3, it is unsurprising 411 that the number of events within the composite endpoint of AESI or death occurred in arm 3 412 where the greatest number of interventions was given. This is supported by the observation 413 that when considering AESI alone, the cumulative incidence of events was significantly 414 greater in arm 3, suggesting that the composite endpoint of AESI or death was driven by the 415 higher rate of AESI in arm 3.

416

Ours is the first RCT to evaluate linezolid in TBM, an important drug in this context. It is the first completed trial to focus on an exclusively HIV-positive population, a vulnerable group in TBM. It is also the first study to date to systematically evaluate the safety of a novel drug regimen containing enhanced antitubercular treatments alongside a host directed therapy in

421 TBM. To improve outcomes in TBM therapeutic advance must simultaneously aim to 422 enhance bacterial clearance within the CNS which controlling the dysregulated host 423 inflammatory response. Our data provides rationale for the safe use of high-dose rifampicin 424 and linezolid in TBM and supports ongoing evaluation of the efficacy of these drugs in a 425 phase 3 trial. It is less clear whether high-dose aspirin is safe in this context. Given the 426 results of previous studies which did not demonstrate any safety concerns, as well as its 427 potential to target key pathways which play a role in the pathogenesis of TBM a larger study 428 is now required to see if potential harm is offset by a morbidity and mortality benefit.

429

431

430 AKNOWLEDGMENTS

432 We would like to thank firstly the participants and their carers for agreeing to take part in the 433 study. We would like to acknowledge staff at referring hospitals, at Western Cape and 434 Eastern Cape provincial governments, and at UCT Clinical Research Centre for their help 435 with making the study a success. We would like to thank the Data Safety and Management 436 Board for their advice and guidance throughout the trial, namely; Professor David Lalloo 437 (chair, Liverpool School for Tropical Medicine), Dr David Meya (College of Health Sciences, 438 Makerere University and Division of Infectious Diseases and International Medicine, 439 University of Minnesota), Dr Evelyne Kestelyn (Clinical Trials Unit, Centre for Tropical 440 Medicine and Global Health, University of Oxford), Dr Maryline Bonnet (Institute of Research for Development, France), Dr Angela Crook, (MRC Clinical Trials Unit, University College 441 442 London). 443 444 445 446 447 448

449

451 **REFERENCES**

452

- 453 1. Marais S, Pepper DJ, Schutz C, Wilkinson RJ, Meintjes G. Presentation and
- 454 outcome of tuberculous meningitis in a high HIV prevalence setting. *PLoS One*.
- 455 2011;6(5):e20077. doi:10.1371/journal.pone.0020077
- 456 2. Lammie GA, Hewlett RH, Schoeman JF, Donald PR. Tuberculous cerebrovascular
- 457 disease: a review. *J Infect*. Sep 2009;59(3):156-66. doi:10.1016/j.jinf.2009.07.012
- 458 3. Misra UK, Kumar M, Kalita J. Seizures in tuberculous meningitis. *Epilepsy Res.* Dec
- 459 2018;148:90-95. doi:10.1016/j.eplepsyres.2018.10.005
- 460 4. Marais S, Roos I, Mitha A, Mabusha SJ, Patel V, Bhigjee AI. Spinal Tuberculosis:
- 461 Clinicoradiological Findings in 274 Patients. *Clin Infect Dis.* Jun 18 2018;67(1):89-98.
- 462 doi:10.1093/cid/ciy020
- 463 5. Davis AG, Nightingale S, Springer PE, et al. Neurocognitive and functional
- 464 impairment in adult and paediatric tuberculous meningitis. *Wellcome Open Res.* 2019;4:178.
- 465 doi:10.12688/wellcomeopenres.15516.1
- 466 6. Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults
- 467 and children. *Tuberculosis (Edinb)*. Sep 2010;90(5):279-92. doi:10.1016/j.tube.2010.07.002
- 468 7. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and
- 469 moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.

470 Lancet Infect Dis. Jan 2013;13(1):27-35. doi:10.1016/S1473-3099(12)70264-5

- 8. Heemskerk AD, Bang ND, Mai NT, et al. Intensified Antituberculosis Therapy in
- 472 Adults with Tuberculous Meningitis. *N Engl J Med.* Jan 14 2016;374(2):124-34.
- 473 doi:10.1056/NEJMoa1507062
- 474 9. Cresswell FV, Meya DB, Kagimu E, et al. High-Dose Oral and Intravenous
- 475 Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human
- 476 Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label
- 477 Randomized Controlled Trial. *Clin Infect Dis.* Sep 7 2021;73(5):876-884.
- 478 doi:10.1093/cid/ciab162

- 479 10. World Health Organisation (WHO). World Health Organisation consolidated
- 480 guidelines on drug-resistant tuberculosis treatment. 2019;
- 481 11. Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal
- 482 fluid/blood-brain barrier for treatment of central nervous system infections. *Clin Microbiol*
- 483 *Rev.* Oct 2010;23(4):858-83. doi:10.1128/CMR.00007-10
- 484 12. Li H, Lu J, Liu J, Zhao Y, Ni X, Zhao S. Linezolid is Associated with Improved Early
- 485 Outcomes of Childhood Tuberculous Meningitis. *Pediatr Infect Dis J.* Jun 2016;35(6):607-10.
- 486 doi:10.1097/INF.000000000001114
- 487 13. Sun F, Ruan Q, Wang J, et al. Linezolid manifests a rapid and dramatic therapeutic
- 488 effect for patients with life-threatening tuberculous meningitis. *Antimicrob Agents*
- 489 Chemother. Oct 2014;58(10):6297-301. doi:10.1128/AAC.02784-14
- 490 14. Zhang X, Falagas ME, Vardakas KZ, et al. Systematic review and meta-analysis of
- the efficacy and safety of therapy with linezolid containing regimens in the treatment of
- 492 multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis. Apr
- 493 2015;7(4):603-15. doi:10.3978/j.issn.2072-1439.2015.03.10
- 494 15. Wasserman S, Brust JCM, Abdelwahab MT, et al. Linezolid toxicity in patients with
- 495 drug-resistant tuberculosis: a prospective cohort study. J Antimicrob Chemother. Mar 31
- 496 2022;77(4):1146-1154. doi:10.1093/jac/dkac019
- 497 16. Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant
- 498 Pulmonary Tuberculosis. *N Engl J Med*. Mar 5 2020;382(10):893-902.
- 499 doi:10.1056/NEJMoa1901814

500 17. Richman IB, Owens DK. Aspirin for Primary Prevention. Med Clin North Am. Jul

- 501 2017;101(4):713-724. doi:10.1016/j.mcna.2017.03.004
- 502 18. Botting RM. Vane's discovery of the mechanism of action of aspirin changed our
- 503 understanding of its clinical pharmacology. *Pharmacol Rep.* May-Jun 2010;62(3):518-25.
- 504 doi:10.1016/s1734-1140(10)70308-x

- 505 19. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation:
- 506 impact of aspirin and statins. *Circ Res.* Nov 12 2010;107(10):1170-84.
- 507 doi:10.1161/CIRCRESAHA.110.223883
- 508 20. Mai NT, Dobbs N, Phu NH, et al. A randomised double blind placebo controlled
- 509 phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults. *Elife*.
- 510 Feb 27 2018;7doi:10.7554/eLife.33478
- 511 21. Schoeman JF, Janse van Rensburg A, Laubscher JA, Springer P. The role of aspirin
- 512 in childhood tuberculous meningitis. *J Child Neurol*. Aug 2011;26(8):956-62.
- 513 doi:10.1177/0883073811398132
- 514 22. Misra UK, Kalita J, Nair PP. Role of aspirin in tuberculous meningitis: a randomized
- 515 open label placebo controlled trial. *J Neurol Sci*. Jun 15 2010;293(1-2):12-7.
- 516 doi:10.1016/j.jns.2010.03.025
- 517 23. Davis AG, Wasserman S, Maxebengula M, et al. Study protocol for a phase 2A trial
- 518 of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or
- 519 without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]. Wellcome Open
- 520 Res. 2021;6:136. doi:10.12688/wellcomeopenres.16783.1
- 521 24. Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case
- 522 definition for use in clinical research. *Lancet Infect Dis.* Nov 2010;10(11):803-12.
- 523 doi:10.1016/S1473-3099(10)70138-9
- 524 25. South Africa Department of Health National Tuberculosis Management Guidelines.525 2014;
- 526 26. Wasserman S, Davis A, Stek C, et al. Plasma Pharmacokinetics of High-Dose Oral
- 527 versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized
- 528 Controlled Trial. Antimicrob Agents Chemother. Jul 16 2021;65(8):e0014021.
- 529 doi:10.1128/AAC.00140-21
- 530 27. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution
- 531 inflammatory syndrome: case definitions for use in resource-limited settings. *Lancet Infect*
- 532 Dis. Aug 2008;8(8):516-23. doi:10.1016/S1473-3099(08)70184-1

- _

561 FIGURES

562

563 Figure 1: Consolidated Standards of Reporting Trials (CONSORT) diagram



- 564
- 565
- 566 Abbreviations: Rif, rifampicin
- 567 *patient randomized but withdrawn prior to receiving study IP due to emergence of
- 568 exclusion criteria
- 569 Legend: CONSORT diagram to describe recruitment and arm allocation. Reasons for
- 570 screening exclusions and early study withdrawals are listed in Tables S1 and S2
- 571
- 572
- 573
- 574
- 575
- 576
- 577
- 578

579 Figure 2: Time to worst grade AESI or death



- 591
- 592
- 593

594 Figure 3 Time to death



610 Figure 4 Time to AESI



Kaplan-Meier analysis of time to AESI, comparing arm 1, 2 and 3 (a), and arm 2 and 3

613 combined vs arm 1 (b).



631 Figure 5: Functional outcome at day 56 as defined by Modified Rankin Scale

635 Figure 3a demonstrates a comparison between good outcome (MRS 0-3) vs bad outcome

636 stratified by arm at day 56. Figure 3b compares change in MRS between enrolment and day

- 637 56, across treatment arms.
- 638

640 Figure 6: Change in CSF parameters over time



642 Spaghetti plots for CSF parameters (lymphocyte count (a), polymorphonuclear cells (b),

643 glucose (c), protein (d)) plotted as individual values over time (faint lines), with mean values

```
644 for each treatment arm represented by superimposed line (bold lines).
```

TABLES

Table 1: Adverse events of special interest (AESI) assessed in the trial

AESI	Investigational	Objective measure
	product	
Gastrointestinal	Aspirin	Clinical and laboratory measures to
haemorrhage		suggest haemorrhage
Intracerebral haemorrhage	Aspirin	Radiological evidence of haemorrhage
Transaminitis	Rifampicin	ALT, bilirubin (DAIDS criteria, Grade 3
		and 4)
Anaemia	Linezolid	Hb (DAIDS criteria, Grade 3 and 4)
Neutropenia	Linezolid	Neutrophils (DAIDS criteria, Grade 3
		and 4)
Thrombocytopenia	Linezolid	Plt count (DAIDS criteria, Grade 3 and
		4)
Peripheral Neuropathy	Linezolid	Full neurological history and
		examination, BPNS, mTNS
Change in LogMAR score	Linezolid	Visual acuity measured by logMAR chart
(visual acuity)		(or tumbling E chart in illiterate
		participants)

661 Abbreviations: ALT, alanine transaminase; DAIDS, Division of AIDS; BPNS, Brief Peripheral

662 Neuropathy Score; mTNS, modified Total Neuropathy Score.

Table 2: Baseline characteristics

	Arm 1 (n=20)	Arm 2 (n=15)	Arm 3 (n=16)
Age, median (IQR) years	39.5 (34-48.5)	37 (34.5–42.5)	41.5 (31.8-46)
Gender, male n (%)	10 (50)	10 (66.7)	16 (62.5)
Uniform case definition, n (%) - Definite - Probable - Possible	8 (40) 5 (25) 7 (35)	3 (20) 4 (26.7) 8 (53.3)	6 (37.5) 4 (25.0) 6 (37.5)
BMRC TBM Grade, n (%) - Grade 1 - Grade 2 - Grade 3	11 (55) 8 (40) 1 (5)	11 (73.3) 4 (26.7) 0 (0)	8 (50) 8 (50) 0 (0)
CD4 T-cell count, median (IQR), cells/µL	116.5 (58.6-283)	131 (82.5-186)	158.5 (85.5-331.5)
HIV viral load, median (IQR), copies/mL	89,150 (1000-203,711)	37,960 (2428 – 394,839)	2686 (1361-777,620)
ART status, n (%) - On ART - Previous ART - ART naive	6 (30) 3 (15) 11 (55)	5 (33) 6 (40) 4 (27)	5 (31) 5 (31) 6 (38)
Of those on ART, duration in weeks, median (range)	288.9 (22.4-459.3)	23.7 (0.4-83.6)	355 (2.9-879.1)
CSF cell count/biochemical data available (n)	17	14	13
Polymorphonuclear cells, median (IQR), cells/ µL	13 (0-85)	4 (2-16)	16 (3-22)
Lymphocytes, median (IQR), cells/ µL	63 (10-259)	79 (11-218)	82 (28-278)
Protein, mg/dL	1.78 (1.13-3.13)	1.89 (0.95-4.2)	1.9 (1.32-2.99)
CSF Glucose, mg/dL	2.2 (0.9-2.5)	2.4 (1.9-2.9)	1.7 (1.2-3.3)
Baseline radiology available (n)	16	12	11
Hydrocephalus n (%)	1 (6.3)	1 (8.3)	1 (9.1)
Meningeal enhancement n, (%)	4 (25)	2 (16.7)	6 (54.5)
Tuberculoma(s) n, (%)	1 (6.3)	2 (16.7)	2 (18.2)
Infarct(s) n. (%)	4 (25)	1 (8.3)	3 (27.3)

Abbreviations: IQR, interquartile range; ART, antiretroviral therapy; BMRC, British Medical Research

Table 3: AESI by treatment arm

	Arm 1 (n=20)	Arm 2 (n=14)	Arm 3 (n=16)	p value **
Bleeding, n* (%)	0 (0)	0 (0)	1 (6)	0.338
Transaminitis, n (%)	0 (0)	0 (0)	2 (13)	0.109
Hematological, n (%)	2 (10)	0 (0)	1 (6)	0.481
Peripheral Neuropathy, n (%)	2 (10)	2 (14)	4 (25)	0.46
Change in LogMAR score, n (%)	0 (0)	2 (14)	2 (13)	0.231

*individuals with an event

** arm 3 *v*s arm 1

Table 4: Details of AESI by event

AE name	Treatment arm	Days of treatment	DAIDS grade	Pre- existing	Outcome
Melaena	3	1	1	No	Two episodes of black stool. No associated change in Hb or urea. Aspirin stopped and not restarted as per protocol. No further events.
Transaminitis	3	16	3	No	Improved to grade 2 but not restarted on high-dose rifampicin at discretion of site PI.
Transaminitis	3	6	4	No	Improved, successfully rechallenged with rifafour FDC. High-dose rifampicin not restarted per protocol.
Neutropenia	1	13	3	Yes	No change in study medication (arm 1)
Neutropenia	3	28	3	No	Linezolid stopped, resolved. Not restarted.
Anemia	1	28	3	No	No change in study medication (arm 1)
Neurosensory symptoms	1	10	2	No	No change in study medication (arm 1). Normal at subsequent visit.
Neurosensory symptoms	1	6	2	No	No change in study medication (arm 1). Normal at subsequent visit.
Neurosensory symptoms	2	3	1	No	Linezolid stopped. MRI show anterior cord changes (possible ischaemic or inflammatory aetiology). Not restarted on linezolid although felt clinically not to be consistent with peripheral neuropathy.
Neurosensory symptoms	2	7	1	No	All study medication stopped due to relocation of participant and therefore withdrawal from study. No follow up BPNS performed.
Bilateral lower limb weakness	3	18	2	No	Linezolid stopped. MRI showed changes consistent with TB radiculopathy//arachnoiditis. Linezolid not restarted
Paresthesia left leg	3	18	1	No	at discretion of site PI, although clinically unlikely peripheral neuropathy.
Neurosensory symptoms	3	3	1	No	Linezolid stopped. Normal at subsequent visit although linezolid not restarted at discretion of site PI.
Neurosensory symptoms	3	10	1	No	Linezolid stopped. Participant subsequently died, cause of death not related to linezolid.
Asymptomatic increase in BPNS	3	13	1	No	Linezolid stopped. Normal at subsequent visit. Linezolid restarted at 600mg as per protocol.
Increase in LogMAR	2	56	1	No	Noted on day 56 visit, therefore no change in study medication. No follow up notes.
Increase in LogMAR	2	55	1	No	Optic neuropathy ruled out by ophthalmology. Linezolid restarted.
Change in visual acuity with related change in LogMAR	3	42	4	No	Seen by ophthalmology. Diagnosis: Parietal stroke +/- ethambutol related optic neuropathy.
Increase in LogMAR	3	55	1	No	Noted on day 56 visit, therefore no change in study medication. No follow up notes.

Abbreviations: Hb; haemoglobin; FDC, fixed dose combination; BPNS, Brief Peripheral Neuropathy Score; LogMAR, Logarithm of the Minimum Angle of Resolution.; MRI, Magnetic Resonance Imaging; PI, principal

investigator.

1 Table 5: Timing and cause of death prior to day 56

Cause of death	Treatment Arm	Days of IP
Renal Failure	1	11
TB Meningitis	1	15
TB Meningitis	1	2
TB Meningitis	2	8
TB Meningitis	2	0*
Pulmonary embolism	3	39
TB Meningitis	3	6
TB Meningitis	3	3

3 *death prior to receiving study IP and therefore excluded from modified intention to treat

- 4 population analysis

21 SUPPLEMENTARY MATERIAL

22

23 Figure S1: Study schedule

24



25

- 26 Legend: Study design schematic describing randomisation to study arms, treatment
- 27 intervention per am, visit schedule, overview of clinical procedures and timepoints relating to
- 28 primary and secondary endpoint data collection
- 29 Abbreviations: RHZE: Rifampicin, Isoniazid, Pyrazinamide, Ethambutol; R₁₀: Rifampicin
- 30 10mg/kg/day; R₃₅: Rifampicin 35mg/kg/day; LZD: Linezolid; ASA; Aspirin;
- 31 32

33

- -
- 35
- 36
- 37
- 38
- 39
- 40
- 41

42 Table S1: Reasons for screening exclusion.

43

Reason*	n	%
Chronic aspirin or NSAID use	9	13.2
HIV uninfected	8	11.8
Investigator discretion	8	11.8
Received more than 5 days of anti-TB treatment in 30 days prior to	7	10.3
enrolment		
Not 'possible', 'probable' or 'definite' TBM	6	8.8
Haemoglobin < 8 g/dL	5	7.4
INR > 1.4	4	5.9
No consent for enrolment given by the patient	3	4.4
Peripheral neuropathy scoring Grade 3 or above on modified BPNS	3	4.4
Standard TB treatment contraindicated	2	2.9
Known rifampicin resistance during this episode	2	2.9
Previous drug resistant TB	2	2.9
Uses a 'disallowed medication' that cannot safely be stopped	2	2.9
Pregnant (>17 weeks at baseline)	1	1.5
Allergy to RHZE, LZD, aspirin	1	1.5
Died before enrolment	1	1.5
Evidence of bacterial or cryptococcal meningitis	1	1.5
eGFR < 20	1	1.5
Platelet count < 50 109/L	1	1.5
Relocation prior to enrolment	1	1.5

44 Abbreviations: NSAID, non-steroidal anti-inflammatory drug; BPNS; brief peripheral

45 neuropathy score; Rif, rifampicin; RHZE; rifafour; LZD, linezolid; ASA, aspirin

46 *more than one reason can be assign to each participant

47 Table S2: Reason for study withdrawals prior to day 56

Withdrawal	Reason
1	Participant relocated to Malawi and therefore unable to attend study follow
	up visits
2	Participant relocated to Kwazulu-Natal and therefore unable to attend
	study follow up visits
3	Participant withdrew consent
4	Participant withdrew consent
5	Participant developed acute psychosis and was unsafe to follow up
6	Participant lost to follow up
	•

66 Box S1: Eligibility Criteria

67	In	clusion criteria							
68	•	Age >18 years							
69	•	proven HIV-1 seropositivity							
70	•	Diagnosis of 'possible', 'probable' or 'definite' TBM							
71	Ex	Exclusion criteria							
72	•	Rifampicin-resistant <i>M.tb</i> detected on any clinical specimen;							
73	•	History of allergy or hypersensitivity to RIF, isoniazid, ethambutol, pyrazinamide, LZD or							
74		ASA;							
75	•	Received more than 5 days of antitubercular therapy in the 30 days prior to screening;							
76	•	Receipt of regular daily ASA or NSAID prior to TBM diagnosis							
77	•	CSF unobtainable by lumbar puncture or another procedure;							
78	•	Evidence of bacterial or cryptococcal meningitis;							
79	•	Severe concurrent uncontrolled opportunistic infection including, but not limited to, active							
80		cytomegalovirus-associated disease, Kaposi sarcoma, Pneumocystis jirovecii							
81		pneumonia, HIV related or unrelated malignancy, or gastrointestinal bleeding;							
82	•	Any other form of immunosuppressive therapy, including antineoplastic and biologic							
83		agents, apart from corticosteroids;							
84	•	More than 17 weeks pregnant at baseline;							
85	•	Peripheral neuropathy scoring Grade 3 or above on the BPNS;							
86	•	Any disease or condition in which the use of the standard anti-TB drugs (or any of their							
87		components) are contraindicated. This includes, but is not limited to, allergy to any TB							
88		drug or their components;							
89	•	The presence of one or more of the following:							
90	-	Estimated glomerular filtration rate (eGFR) < 20ml/min/1.73 m2*							
91	-	INR > 1.4 and/or clinical evidence of liver failure or decompensated cirrhosis;							
92	-	Haemoglobin < 8.0 g/dL;							
93	-	Platelets < 50 x109 /L;							
94	-	Neutrophils < 0.5 x 109 cells/L;							
95	•	Any disease or condition in which any of the medicinal products listed in the section							
96		pertaining to prohibited medication is used and cannot be safely stopped;							
97	•	Known or suspected history of drug abuse or any other reason that is, in the opinion of							
98		investigators, sufficient to compromise the safety or cooperation of the participant.							
99	*C	alculated using the Cockcroft-Gault equation; INR: International normalised ration; BPNS: Brief Peripheral							
100	Ne	uropathy Score; NSAID: Non Steroidal Anti Inflammatory Drug;							